SCHEMBL13009367

SCHEMBL13009367

c1ccc(-c2c3cc(N4c5ccccc5Oc5ccccc54)ccc3c(-c3cccc4ccccc34)c3ccc(N4c5ccccc5Oc5ccccc54)cc23)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE6D O43924 1/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPK1 P28482 2/20 0.34
ATM Q13315 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
POLB P06746 1/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
SOS1 Q07889 1/20 0.32
GPR84 Q9NQS5 1/20 0.31
ESR1 P03372 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13009401 1.00 PDE6D (0.34) PDE6DKDM4EMAPK1ATMALDH1A1
SCHEMBL13008675 0.98 PDE6D (0.38) PDE6DKDM4EMAPK1ATMALDH1A1
SCHEMBL13427260 0.95 PDE6D (0.33) PDE6DKDM4EMAPK1ATMALDH1A1
SCHEMBL13427311 0.94 PDE6D (0.34) PDE6DKDM4EMAPK1ATMALDH1A1
SCHEMBL13427306 0.94 ENPP3 (0.34) PDE6DKDM4EMAPK1ATMALDH1A1
SCHEMBL13427264 0.94 PDE6D (0.36) PDE6DKDM4EMAPK1ATMALDH1A1
SCHEMBL13009415 0.94 POLB (0.38) KDM4EMAPK1ATMALDH1A1MAPT
SCHEMBL13008308 0.93 POLB (0.33) PDE6DKDM4EMAPK1ATMALDH1A1
SCHEMBL13009406 0.93 PDE6D (0.33) PDE6DKDM4EMAPK1ATMALDH1A1
SCHEMBL13427320 0.92 PDE6D (0.33) PDE6DKDM4EMAPK1ATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2256176-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-12-01 EP disclosed
US-20100051106-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-03-04 US disclosed
US-20100051106-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-03-04 US disclosed
EP-2141214-A2 Novel organic electroluminescent compounds and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100051106-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same RPL36, RPL39, RPL36A PDE6D 3559/4885KDM4E 4138/4885MAPK1 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.